Vol. 1 No. 7 (2021)
Reimbursement Recommendations

Dinutuximab (Unituxin)

Published July 28, 2021

Key Messages

  • CADTH recommends that Unituxin (in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor [GM-CSF]) should be reimbursed by public drug plans for the treatment of patients with relapsed or refractory high-risk neuroblastoma if certain conditions are met.
  • Unituxin should only be reimbursed if delivered in a specialized pediatric cancer centre by health care professionals with experience and knowledge of managing neuroblastoma and the toxicities of anti-GD2 therapy and if the cost of Unituxin is reduced.
  • Unituxin should only be covered for patients who have not had previous treatment for relapsed or refractory high-risk neuroblastoma or have not had a severe reaction or progressive disease with upfront anti-GD2 immunotherapy.